Medical
-
California pharmaceutical company Inverseon has announced that it will redirect its development program for INV102, an inverse beta agonist, to focus on smoking cessation and COPD rather than asthma, although it is continuing to seek… Read more . . .
-
According to an article published online in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine, only about a third of asthma patients not using an inhaled corticosteroid (ICS) and 17% of… Read more . . .
-
An unnamed angel investment group is providing up to $3.5 million dollars to St. Renatus for Phase 3 clinical trials of its nasal mist dental anesthesia. St. Renatus announced in March 2011 that it had… Read more . . .
-
GlaxoSmithKline and Theravance have announced the completion of Phase 3 studies of their Relovair fluticasone furoate/vilanterol DPI for COPD. One Phase 3 study for the treatment of asthma remains to be completed. Despite the fact… Read more . . .
-
According to Pearl Therapeutics, it has completed two Phase 2b clinical studies of PT003, its inhaled combination bronchodilator for the treatment of moderate-to-severe COPD, and is “on-track to commence Phase 3 program in 2012.” One… Read more . . .
-
Civitas Therapeutics has announced positive results from a Phase 1 clinical study of its CVT-301 inhaled dry powder formulation of levodopa (L-dopa) for the treatment of Parkinson’s disease. According to the company, the study showed… Read more . . .
-
ISTA Pharmaceuticals says that it has initiated a Phase 2 study of its Beposone bepotastine besilate/steroid combination nasal spray for the treatment of seasonal allergic rhinitis. Approximately 600 patients with allergic rhinitis caused by mountain… Read more . . .
-
Pulmatrix has presented data at the 11th US-Japan Symposium on Drug Delivery Systems in Hawaii that it says demonstrate the superiority of its iSPERSE inhalation platform over lactose formulations for combination dry powder inhalers. The… Read more . . .
-
An article published in the December 8, 2011 issue of the New England Journal of Medicine describes a proof of principle study in which an intranasal dry powder vaccine significantly reduced Norwalk virus gastroenteritis and… Read more . . .
-
Pearl Therapeutics has announced positive top-line results from a Phase 2b dose-ranging study of its PT001 glycopyrrolate (GP) MDI in patients with moderate-to-severe COPD. The randomized, double-blind study compared 4 doses of the PT001 MDI… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here


